Galmed Pharmaceuticals Lt... (GLMD)
1.97
-0.17 (-7.94%)
At close: Mar 03, 2025, 3:54 PM
1.94
-1.52%
After-hours: Mar 03, 2025, 04:18 PM EST
No 1D chart data available
| Bid | 1.9 |
| Market Cap | 3.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -151.59M |
| EPS (ttm) | 69.72 |
| PE Ratio (ttm) | 0.03 |
| Forward PE | -2.83 |
| Analyst | n/a |
| Ask | 2.08 |
| Volume | 25,085 |
| Avg. Volume (20D) | 31,563 |
| Open | 2.33 |
| Previous Close | 2.14 |
| Day's Range | 1.90 - 2.33 |
| 52-Week Range | 1.90 - 23.80 |
| Beta | 0.72 |
About GLMD
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2014
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GLMD
Website https://www.galmedpharma.com
5 months ago
-11.93%
Galmed Pharmaceuticals shares are trading lower. T...
Unlock content with
Pro Subscription
5 months ago
+21.74%
Galmed Pharmaceuticals shares are trading higher after the company announced plans to broaden its drug development activities with two additional programs over the next two years.
